Abstract:BACKGROUND: Osteosarcoma (OS) is the most common primary malignant bone tumor in adolescents. The molecular mechanism behind OS progression and metastasis remains poorly understood, which limits the effectiveness of current therapies. RNA N6-methyladenosine (m6A) modification plays a critical role in influencing RNA fate. However, the biological significance of m6A modification and its potential regulatory mechanisms in the development of OS remain unclear.METHODS: Liquid chromatography-tandem mass spectrometry (LC-MS/MS), dot blotting, and colorimetric ELISA were used to detect m6A levels. Western blotting, quantitative real-time PCR (RT-qPCR) and immunohistochemistry (IHC) were used to investigate METTL14 expression levels. Methylated RNA immunoprecipitation sequencing (MeRIP-seq) and transcriptomic RNA sequencing (RNA-seq) were used to screen the target genes of METTL14. RNA pull-down and RNA immunoprecipitation (RIP) assays were conducted to explore the specific binding of target genes and relevant m6A "readers". RNA stability and polysome analysis assays were used to detect the half-lives and translation efficiencies of the downstream genes of METTL14. IHC and clinical data were applied to explore the clinical correlations of METTL14 and its downstream target genes with the prognosis of OS.FINDINGS: We observed the abundance of m6A modifications in OS and revealed that METTL14 plays an oncogenic role in facilitating OS progression. MeRIP-seq and RNA-seq revealed that MN1 is a downstream gene of METTL14. MN1 contributes to tumor progression and all-trans-retinoic acid (ATRA) chemotherapy resistance in OS. Mechanistically, MN1 is methylated by METTL14, specifically in the coding sequence (CDS) regions, and this modification is recognized by the specific m6A reader insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) to prevent MN1 mRNA degradation and promote it translation efficiency. IHC showed that MN1 expression was positively correlated with METTL14 and IGF2BP2 expression in OS tissues. The METTL14-IGF2BP2-MN1 panel demonstrated more promising prognostic value for OS patients than any of these molecules individually.INTERPRETATION: Our study revealed that METTL14 contributes to OS progression and ATRA resistance as an m6A RNA methylase by regulating the stability and translation efficiency of MN1 and thus provides both an underlying biomarker panel for prognosis prediction in OS patients.FUNDING: This work was supported by the National Natural Science Foundation of China (Grants 81972510 and 81772864).

METTL3 upregulates COPS5 expression in osteosarcoma in an m6A-related manner to promote osteosarcoma progression

The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1

ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression

Mtorc1 Accelerates Osteosarcoma Progression Via M6a-Dependent Stabilization of USP7 Mrna

m6A-dependent upregulation of TRAF6 by METTL3 is associated with metastatic osteosarcoma

METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma Via Modulating the M6a Amount of PRMT5 and PD-L1

METTL16 promotes osteosarcoma progression by downregulating VPS33B in an m6 A-dependent manner

Methyltransferase-like 3 Promotes Cervical Cancer Metastasis by Enhancing Cathepsin L Mrna Stability in an N6-methyladenosine-dependent Manner

METTL16 promotes osteosarcoma progression by downregulating VPS33B in an m6A‐dependent manner

METTL3 Promotes Oral Squamous Cell Carcinoma Progression by Enhancing SLC7A11 mRNA Stability via m6A-Mediated IGF2BP2 Binding

METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma

M6a Methyltransferase METTL3 Promotes Oral Squamous Cell Carcinoma Progression Through Enhancement of IGF2BP2-mediated SLC7A11 Mrna Stability

Dysregulated m6A-Related Regulators Are Associated With Tumor Metastasis and Poor Prognosis in Osteosarcoma

METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma

METTL3/YTHDF1 Stabilizes CORO6 Expression Promoting Osteosarcoma Progression Through Glycolysis

ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner

METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1

IDDF2018-ABS-0233 N6-adenosine Methyltransferase METTL3 Promotes Tumour Metastasis Via SOX2 MRNA M6A Modification in Colorectal Carcinoma

The M6A methyltransferase METTL3 regulates proliferation in esophageal squamous cell carcinoma

m6A regulators are associated with osteosarcoma metastasis and have prognostic significance: A study based on public databases

METTL3 promotes the progression of osteosarcoma through the N6-methyladenosine modification of MCAM via IGF2BP1